Ce n'est pas tous les jours que vous devez choisir une mutuelle santé, et réussir à dénicher la perle rare peut s'avérer difficile ! Heureusement, en faisant preuve de méthode, vous pouvez tout à fait ...

The clinical study is designed to evaluate the performance of NASARIX in adults with allergic rhinitis. NASARIX utilizes Polyrizon's proprietary Capture and Contain™ technology, which forms a ...

Now in its 12th consecutive year and the largest comedy tour of its kind in the world, the UK Winter Comedy Tour will run across a string of dates from 11 December to 31 December, giving audiences the ...

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce ...

CLINICAL TRIALS – PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer’s disease (#P055).

Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 ...

Single-dose CLD-401 induced tumor regression and complete response in 80% of mice in EMT6 breast tumor model Building on the growing clinical evidence supporting T-cell engagers in solid tumors, data ...

Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder ...

All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on conventional PCR tests; Four of five completed patients ...

Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an ...

Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced ...

Jefferies Global Healthcare Conference November 16–19, 2026 London, United Kingdom Presentation Details: Fireside Chat with Mark Iwicki, CEO of Inhibikase and Dennis Ding, Jefferies Research on Monday ...